ADMA Biologics, Inc. (ADMA) Dividend History

Company News

• 3 Mid-Cap Medical Stocks Outperforming the Market

  Several mid-cap medical and biotechnology stocks have outperformed the broader market in 2025, including Penumbra Inc, TransMedics Group Inc, and ADMA Biologics Inc. These companies have shown strong momentum, bullish analyst sentiment, and potential for continued upside.

  Investing.com
• ADMA Biologics Statement on Tariffs

  ADMA Biologics, a U.S.-based biopharmaceutical company, has reiterated its strategic advantage through fully domestic manufacturing, commercialization, and supply chain operations. The company's vertically integrated U.S.-based infrastructure ensures supply chain robustness, regulatory compliance, and alignment with federal and private sector preferences for U.S.-made products.

  GlobeNewswire Inc.
• BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls

  ADMA Biologics, Inc. is being investigated by Block & Leviton for potential securities law violations following a delay in filing its Form 10-K and an ongoing audit by KPMG focused on evaluating internal controls.

  GlobeNewswire Inc.
• BFA Law is Investigating ADMA BIOLOGICS for Securities Fraud after Stock Plummets 20%; Contact the Firm if You Suffered Losses (Nasdaq:ADMA)

  ADMA Biologics, a biopharmaceutical company, saw its stock plummet 20% after the surprise resignation of its independent outside auditor. BFA Law is investigating the company for potential securities fraud.

  GlobeNewswire Inc.
• ADMA FRAUD ALERT: BFA Law Notifies ADMA Biologics Investors of Ongoing Securities Fraud Investigation after Auditor Resigns and Urges You to Contact the Firm (Nasdaq:ADMA)

  ADMA Biologics, a biopharmaceutical company, is under investigation for potential securities fraud after its independent auditor unexpectedly resigned, causing a significant drop in the company's stock price.

  GlobeNewswire Inc.